Replies to post #70071 on MultiCorp International Inc (MCIC)

[Klusserdeklus]

ONE DOLLAR ! my exit pps, nice, let's go lol

[tonysib]

This is a joke/ Based on our projected revenues and the industry average forward P/E ratio of 30, our management believes the share price should be in the $.90 - $1.00 range," stated Mr. Paul D. Lisenby, Chairman and CEO of XTend Medical.
The complete pr is a what if!!!!!!!!!! Can you pay your bills on projected revenues?

[skinut]

Didn't Dan once promise to buy back shares of SMMW? We all saw where that got us.

What's the saying..."You can't teach an old Dog(SMMW) new tricks." or "But you can teach a new Dog(XMDC) old tricks!"

[k9narc]

The PPS was around a nickle when Paul dropped this PR....

XTend Medical (XMDC) Announces Stock Repurchase Program


Company to Repurchase up to 5M Shares

SUN VALLEY, CA, Nov 27, 2007 (MARKET WIRE via COMTEX) -- XTend Medical Corporation (PINKSHEETS: XMDC) announced the company's Board of Directors has authorized a stock repurchase program and the company will repurchase up to 5 million shares of the Company's common stock. Transactions may occur from time to time, either on the open market or privately negotiated. The stock repurchase is subject to market conditions, corporate and regulatory requirements. The program authorizes the company to repurchase shares of the company's common stock until March 31, 2008 in open market or private transactions. The company has no obligation to repurchase shares under the program and the program may be suspended or terminated at any time.
"Consistent with our goal to grow the company and deliver long term shareholder value, we feel this program allows us to be opportunistic in buying shares of our stock when favorable market conditions exist while continuing our strategy of developing several telehealth programs that will be presented, and subsequently implemented, into major health care associations. The shares will be held in the company treasury and used for acquisitions, shareholder dividends, and employee incentive programs. The Board's approval of this program shows a strong belief in XTend Medical and its future. This decision was made based on our consideration of the current share price which our management believes is not indicative of the underlying true value of our company. Based on our projected revenues and the industry average forward P/E ratio of 30, our management believes the share price should be in the $.90 - $1.00 range," stated Mr. Paul D. Lisenby, Chairman and CEO of XTend Medical.


Float was a lot lower too.

Strange that a buyback raises the float.